Skip to main content

Table 4 .Study subject end of treatment objective response rates

From: Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer

Best response(n)

UX therapy (n = 43)

Eri therapy (n = 42)

P-value

CR

1

0

 

PR

7

9

 

SD

10

14

 

PD

22

16

 

NA

3

3

 

Total

43

42

 

ORR,%

18.6

21.43

0.745

95%,CI

0.084, 0.334

0.103, 0.368

 
  1. UX (Utidelone plus Capecitabine); Eri(Eribulin). The treatment response was evaluated according to RECIST 1.1. ORR = (CR + PR)/total × 100%. 95% confidence interval Calculated using Clopper Pearson method. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; CI: confidence interval
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us